What is Wedbush’s Forecast for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a report released on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.43) per share for the quarter, down from their previous forecast of ($0.29). Wedbush currently has a “Outperform” rating and a $32.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.21 EPS and FY2028 earnings at $1.24 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million.

DAWN has been the topic of a number of other research reports. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Wednesday. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday. Finally, Bank of America lowered their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $34.86.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $9.44 on Friday. Day One Biopharmaceuticals has a 52-week low of $9.43 and a 52-week high of $18.07. The firm has a market capitalization of $951.99 million, a PE ratio of -9.17 and a beta of -1.46. The business’s 50-day simple moving average is $12.23 and its 200 day simple moving average is $13.41.

Insider Activity

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,064 shares of company stock valued at $651,225 over the last quarter. 8.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in Day One Biopharmaceuticals in the 4th quarter valued at about $27,000. R Squared Ltd bought a new position in Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares during the last quarter. Quest Partners LLC increased its stake in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after buying an additional 7,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after buying an additional 9,603 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.